Bio-Rad Laboratories (BIO) Gains from Investment Securities (2010 - 2026)

Bio-Rad Laboratories (BIO) has reported Gains from Investment Securities for 17 consecutive years, with $33.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 104.29% year-over-year to $33.3 million; the TTM figure through Mar 2026 stood at $98.0 million (up 13.16% YoY), while the FY2025 annual figure was $81.0 million, down 5.92% from the prior year.
• Gains from Investment Securities climbed to $33.3 million in Q1 2026 per BIO's latest filing, from $18.3 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $50.8 million in Q2 2023 and bottomed at $9.4 million in Q3 2022.
• Historically, Gains from Investment Securities has averaged $21.7 million across 5 years, with a median of $18.3 million in 2023.
• Annual changes were most pronounced in 2022 — Gains from Investment Securities soared 390.08% — and 2024, when it slumped 30.65%.
• Bio-Rad Laboratories' Gains from Investment Securities stood at $17.0 million in 2022, then rose by 7.77% to $18.3 million in 2023, then increased by 3.98% to $19.0 million in 2024, then dropped by 3.68% to $18.3 million in 2025, then soared by 81.97% to $33.3 million in 2026.
• Business Quant data shows BIO's Gains from Investment Securities at $33.3 million in Q1 2026, $18.3 million in Q4 2025, and $13.8 million in Q3 2025.